Table 2.
Heterogeneity prior | Crins et al. | Miller et al. | Mozobil | Romiplostim | Krystexxa |
---|---|---|---|---|---|
half‐Normal(1.0) | 0.16 (0.04, 0.78) | 0.59 (0.18, 1.74) | 5.34 (1.80, 15.95) | 0.19 (0.04, 0.80) | 7.14 (1.04, 49.15) |
half‐Normal(0.5) | 0.16 (0.05, 0.49) | 0.60 (0.29, 1.14) | 5.34 (2.73, 10.48) | 0.19 (0.07, 0.53) | 7.14 (1.39, 36.70) |
log‐Normal(‐1.048,1.046) | 0.16 (0.05, 0.58) | 0.60 (0.27, 1.23) | 5.34 (2.56, 11.19) | 0.19 (0.06, 0.60) | 7.14 (1.25, 40.80) |
log‐Normal(‐1.741,1.046) | 0.16 (0.06, 0.45) | 0.60 (0.35, 0.99) | 5.34 (3.18, 8.98) | 0.19 (0.07, 0.49) | 7.14 (1.46, 35.01) |
inv‐Gamma(0.5,0.0076) | 0.16 (0.06, 0.47) | 0.60 (0.35, 1.00) | 5.34 (3.14, 9.08) | 0.19 (0.07, 0.51) | 7.14 (1.39, 36.57) |
inv‐Gamma(0.5,0.0019) | 0.16 (0.06, 0.42) | 0.61 (0.41, 0.90) | 5.33 (3.45, 8.25) | 0.19 (0.08, 0.46) | 7.14 (1.49, 34.08) |